<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Hepatitis C virus infection in liver transplant candidates and recipients</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Hepatitis C virus infection in liver transplant candidates and recipients</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Hepatitis C virus infection in liver transplant candidates and recipients</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Elizabeth C Verna, MD, MSc</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Robert S Brown, Jr, MD, MPH</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Adrian M Di Bisceglie, MD</a></dd><dt><span> </span>Deputy Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Allyson Bloom, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Kristen M Robson, MD, MBA, FACG</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Dec 14, 2021.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Hepatitis C virus (HCV) infection causes approximately 40 percent of all chronic liver disease in the United States. While HCV-associated cirrhosis is one of the most common indications for liver transplantation among adults [<a href="#rid1">1,2</a>], the proportion of transplant waitlist additions for HCV-associated disease in the United States has declined since the introduction of interferon-free, direct-acting antiviral (DAA) therapy [<a href="#rid3">3</a>]. If not treated pretransplant, HCV reinfection of the transplanted liver is near universal and, without effective antiviral treatment post-transplant, can be a major cause of graft failure.</p><p>The major issues related to HCV infection in liver transplant candidates and recipients will be reviewed here. Similar problems arise in patients with HCV who undergo other forms of organ transplantation. (See  <a class="medical medical_review" href="/z/d/html/7310.html" rel="external">"Hepatitis C infection in kidney transplant candidates and recipients"</a>.)</p><p>The natural history and treatment of HCV infection, as well as the selection of patients for liver transplantation, are discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/3672.html" rel="external">"Clinical manifestations and natural history of chronic hepatitis C virus infection"</a> and  <a class="medical medical_review" href="/z/d/html/3673.html" rel="external">"Overview of the management of chronic hepatitis C virus infection"</a> and  <a class="medical medical_review" href="/z/d/html/16592.html" rel="external">"Management of chronic hepatitis C virus infection: Initial antiviral therapy in adults"</a> and  <a class="medical medical_review" href="/z/d/html/15795.html" rel="external">"Management of chronic hepatitis C virus infection: Antiviral retreatment following relapse in adults"</a> and  <a class="medical medical_review" href="/z/d/html/4585.html" rel="external">"Liver transplantation in adults: Patient selection and pretransplantation evaluation"</a>.)</p><p class="headingAnchor" id="H3119866672"><span class="h1">POST-TRANSPLANT CLINICAL COURSE</span></p><p class="headingAnchor" id="H3571984747"><span class="h2">Graft reinfection post-transplant</span><span class="headingEndMark"> — </span>For patients with HCV viremia at the time of transplant, recurrence of HCV infection following liver transplantation is universal [<a href="#rid4">4,5</a>]. Sequencing studies have confirmed that reinfection is with the same viral strain circulating prior to transplant. </p><p>Among individuals with pre-existing HCV infection, infection of the transplanted liver occurs during reperfusion of the allograft in the operating room, since patients remain viremic at the time of transplantation in the absence of antiviral therapy. Although viral levels decline in the first days after removal of the infected liver, they rebound and reach pretransplant levels within 72 hours [<a href="#rid6">6</a>]. Once the graft has been infected, serum HCV RNA levels increase from 4- to 100-fold following liver transplantation [<a href="#rid7">7</a>]. Peripheral monocytes may also harbor virus and act as a source for reinfection of the donor liver [<a href="#rid8">8</a>]. </p><p class="headingAnchor" id="H400724689"><span class="h2">Progression of liver disease post-transplant</span><span class="headingEndMark"> — </span>With the efficacy and increasing use of direct-acting antiviral (DAA) therapy before and after transplant, significant HCV-related progression of liver disease post-transplant should be extremely rare. </p><p>Without successful antiviral therapy, the clinical course of HCV-associated liver disease following liver transplantation is variable, as in the pretransplant setting; the course is overall accelerated compared with the nontransplant natural history. About 20 to 40 percent of post-transplant patients who have not been cured of HCV infection develop progressive histologic damage, with 10 to 20 percent developing cirrhosis in as little as five years post-transplant, and 5 to 10 percent will develop a severe form of recurrence known as fibrosing cholestatic HCV [<a href="#rid5">5,9-16</a>].</p><p>The risk factors leading to these variable patterns of recurrence in individual patients are not well understood. Although several risk factors have been identified, none have permitted clinically important intervention [<a href="#rid17">17-25</a>]. </p><p class="headingAnchor" id="H917209342"><span class="h2">Risk factors for progressive disease</span><span class="headingEndMark"> — </span>Variables that influence the progression of untreated HCV-associated liver disease following orthotopic liver transplantation (OLT) are incompletely understood, but donor characteristics (donor type, age), recipient characteristics (demographics, immune status, and immunosuppressive regimen), and disease characteristics (viral genotype, viral load, and the inflammatory grade of the explanted liver) may be important [<a href="#rid7">7,9-12,26-34</a>].</p><p>In particular, the donor characteristic that most strongly predicts outcome in HCV-viremic liver transplant recipients is donor age. Although grafts from donors aged 60 to 80 years function without a survival disadvantage in patients without HCV infection [<a href="#rid35">35</a>], liver disease related to HCV recurrence may be more severe when older donors are used [<a href="#rid34">34,36-40</a>]. This diminished graft survival may even be seen with donors in their fourth and fifth decades, and the mechanism of interaction is unknown.</p><p class="headingAnchor" id="H4287369580"><span class="h2">Overall post-transplant prognosis</span><span class="headingEndMark"> — </span>Five-year survival after transplantation for HCV-associated liver disease is approximately 60 to 80 percent in series performed prior to the widespread availability of DAA agents, which is comparable to transplants performed for alcohol-associated liver disease and better than historic rates for hepatitis B virus infection, hemochromatosis, or cancer [<a href="#rid10">10,12,14,22,31,41,42</a>]. Nevertheless, overall survival has historically been lower in HCV-viremic recipients compared with recipients without HCV infection [<a href="#rid40">40,43</a>]. Recurrent HCV-related graft failure was the leading cause of death in these patients, though hepatocellular carcinoma is also an important predictor of five-year patient or graft survival [<a href="#rid12">12</a>]. </p><p>The impact of more effective antiviral therapy with DAA regimens is discussed elsewhere. (See <a class="local">'Benefits'</a> below.)</p><p class="headingAnchor" id="H2623102469"><span class="h1">DECIDING TO TREAT BEFORE OR AFTER TRANSPLANT</span><span class="headingEndMark"> — </span>The availability of safe and highly effective HCV therapy with direct-acting antivirals (DAAs) has revolutionized the approach to HCV management in liver transplant candidates and recipients. A major focus of management is determining the optimal timing of therapy relative to transplantation. Antiviral therapy of liver transplant candidates, particularly those who have advanced cirrhosis, should be administered at transplant centers with appropriate expertise. </p><p class="headingAnchor" id="H689806892"><span class="h2">Considerations</span><span class="headingEndMark"> — </span>Deciding whether to treat HCV infection prior to transplant or defer therapy until after transplantation is a key management issue for liver transplant candidates. Although cure of HCV infection prior to transplantation prevents reinfection of the allograft and can improve survival on the transplant waiting list in some patients with HCV-related decompensated cirrhosis, pretransplant antiviral therapy may not be the optimal strategy for selected transplant candidates. Although data informing the decision are limited, the relative benefits of pre- versus post-transplant therapy depend on several factors: </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Likelihood of meaningful clinical response to pretransplant therapy</strong> – Sustained virologic response (SVR) following antiviral therapy can lead to stabilization or improvement in liver function in a majority of patients with decompensated cirrhosis (Childs-Pugh class B and C) [<a href="#rid44">44,45</a>]. As an example, in a trial of <a class="drug drug_general" data-topicid="108951" href="/z/d/drug information/108951.html" rel="external">sofosbuvir-velpatasvir</a>, among 27 patients with decompensated cirrhosis and a baseline <a class="external" href="/external-redirect?target_url=https%3A%2F%2Foptn.transplant.hrsa.gov%2Fresources%2Fallocation-calculators%2Fmeld-calculator%2F&amp;token=iRMJIIdlcCMEXBWgyUXhEj85JXUmTLBxW0uB0IuIJz7WR7PrHBxXi2mI3BwjTJvu4iYyowpPMNpkTBUTjvT81BphmAxTsPpJApITG494Mzc%3D&amp;TOPIC_ID=4583" target="_blank">Model for End-Stage Liver Disease</a> (MELD) score ≥15, 81 percent had improvement, 11 percent had no change, and 7 percent had worsening of the MELD score at 12 weeks post-antiviral therapy [<a href="#rid46">46</a>]. In addition, observational studies have reported that 17 to 33 percent of patients on the transplant waiting list could achieve sufficient clinical improvement with successful antiviral treatment to be removed from the list [<a href="#rid47">47-50</a>]. </p><p></p><p class="bulletIndent1">However, while some improvement in MELD score is common with antiviral therapy, many patients have only modest decreases (eg, 1 to 3 MELD points) that do not correspond to substantial clinical improvements. Furthermore, whether improvements in MELD are sustained in the long term is uncertain. In a study of real-world data from patients with cirrhosis and MELD score ≥10 who underwent antiviral therapy, there was almost no change in median MELD scores from pretreatment values compared with follow-up at a median of four years [<a href="#rid51">51</a>]. It is possible that modest decreases in MELD without resolution of clinical symptoms could inadvertently disadvantage the patient in terms of transplant priority, thus delaying transplant (sometimes referred to as "MELD purgatory"). Thus, it may be overall beneficial to defer treatment until after transplant for selected patients. </p><p></p><p class="bulletIndent1">The clinical features that predict which patients would benefit meaningfully from pretransplant therapy have not been well established. In observational studies, relatively low baseline MELD score (eg, &lt;16), low baseline Child-Pugh score, and the absence of significant complications of portal hypertension including encephalopathy have been associated with meaningful clinical improvement with antiviral therapy [<a href="#rid47">47-50</a>]. </p><p></p><p class="bulletIndent1">Further attempts have been made to identify a specific MELD score under which pretransplant treatment is associated with an overall survival benefit. As an example, in one simulation model based on data from two randomized treatment trials (of <a class="drug drug_general" data-topicid="97562" href="/z/d/drug information/97562.html" rel="external">ledipasvir-sofosbuvir</a> plus <a class="drug drug_general" data-topicid="9860" href="/z/d/drug information/9860.html" rel="external">ribavirin</a> in patients with Child-Pugh class B and C cirrhosis) and data on organ allocation and outcomes from the United Network for Organ Sharing (UNOS), pretransplant antiviral therapy was associated with a survival benefit for patients with a MELD score of 23 to 27, depending on the UNOS region [<a href="#rid52">52</a>]. However, this study was limited by the lack of treatment efficacy data among patients with MELD scores &gt;20 and the lack of sufficient data on risk of disease progression following SVR.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Expected virologic response to therapy</strong> – Patients with Child-Pugh class C cirrhosis have lower SVR rates with antiviral therapy than patients with less advanced disease. Furthermore, if such patients are treated prior to transplant and fail therapy, there is a risk of resultant resistance associated mutations that make selection of a post-transplant antiviral regimen more complicated. Thus, for such patients, deferring therapy until after transplant could maximize the likelihood of treatment success. </p><p></p><p class="bulletIndent1">Among patients with cirrhosis, HCC is also associated with lower SVR rates [<a href="#rid51">51,53,54</a>]; however, antiviral treatment is still successful in the majority of patients with HCC. Thus, in the absence of severe decompensation or short time to transplantation, the likelihood of SVR and its attendant benefits (eg, stabilization of clinical status and prevention of allograft reinfection) are sufficiently high to warrant treatment before transplant in most patients with HCC.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Access to transplant </strong>– As above, if patients have a reduction in MELD score after SVR but symptoms of liver disease do not improve, their access to transplant may be decreased due to the decline in their MELD score ("MELD purgatory"). This potential outcome must be a consideration in deciding when to treat patients who do not have alternative access strategies, such as a living donor or MELD exception points.</p><p></p><p class="bulletIndent1">Utilization of livers from HCV-viremic donors had traditionally reduced waiting time and improved access to transplant for HCV-viremic patients on the liver transplant waiting list. However, as use of HCV-viremic donors among HCV-negative recipients has become more widespread, deferring treatment to facilitate use of an HCV-viremic donor organ is less likely to impact access to transplant. (See <a class="local">'Use of grafts from HCV-viremic donors'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment options</strong> – Several HCV treatment regimens are contraindicated for patients with Child-Pugh class B or C cirrhosis, and such patients thus have fewer options to select among. Thus, deferring therapy until after transplant, with the resultant improvement in organ function, will allow for more treatment options. This may be of particular importance in patients with prior treatment failure.</p><p></p><p class="headingAnchor" id="H1373656677"><span class="h2">Approach</span><span class="headingEndMark"> — </span>The decision to treat HCV infection before or after liver transplant should be individualized and take into account the patient's short-term prognosis, the likelihood of a successful and clinically meaningful response to therapy, access to transplant, and comorbidities [<a href="#rid55">55</a>]. (See <a class="local">'Considerations'</a> above.)</p><p>Taking into account all of these factors, we generally suggest pretransplant antiviral therapy for:</p><p class="bulletIndent1"><span class="glyph">●</span>Patients with Child-Pugh A or B cirrhosis and MELD score &lt;20. Such patients are likely to have virologic and clinically meaningful response to antiviral therapy and could potentially achieve long-term, transplant-free survival with antiviral therapy. However, the MELD threshold under which this is most likely to occur is uncertain, so a score of 20 should not be considered an absolute cut-off. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with access to transplant through living donation or MELD exception points (when the expected waiting time is less than one year). This includes patients with compensated cirrhosis and hepatocellular carcinoma (HCC)-related MELD exception points, who are likely to have improved clinical stability with SVR but are less likely to be disadvantaged by HCV clearance (since they have access to transplant through exception points). </p><p></p><p>Waiting to treat in the post-transplant setting may be a reasonable option for:</p><p class="bulletIndent1"><span class="glyph">●</span>Patients with advanced disease with severe portal hypertension or high MELD (eg, MELD &gt;27). These patients are unlikely to improve with antiviral therapy to an extent that would preclude the need for transplant, and deferring therapy could maximize access to transplant and the likelihood of treatment response. In addition, transplant should not be delayed in this group to complete HCV therapy.</p><p></p><p>Our approach is largely consistent with a consensus statement from the International Liver Transplantation Society [<a href="#rid56">56</a>]. Specifically, that statement suggests:</p><p class="bulletIndent1"><span class="glyph">●</span>Pretransplant antiviral therapy for patients with:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Compensated cirrhosis and HCC</p><p class="bulletIndent2"><span class="glyph">•</span>Decompensated cirrhosis but no HCC when the MELD score is relatively low (eg, &lt;20) and there are no other conditions such as severe portal hypertension that warrant prompt transplantation</p><p class="bulletIndent2"><span class="glyph">•</span>Decompensated cirrhosis and HCC when expected wait time for transplantation is more than three to six months </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Defer antiviral therapy until post-transplant for patients with:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Advanced decompensated cirrhosis with an anticipated wait time less than three months </p><p class="bulletIndent2"><span class="glyph">•</span>Decompensated cirrhosis and HCC with an anticipated wait time less than three to six months</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>An individualized decision for patients with decompensated cirrhosis who do not fit into the groups above</p><p></p><p class="headingAnchor" id="H1587334263"><span class="h1">PRETRANSPLANT ANTIVIRAL THERAPY</span><span class="headingEndMark"> — </span>In general, regimen selection for patients with chronic HCV infection depends on genotype, presence of cirrhosis, degree of hepatic dysfunction, treatment history, and comorbidities. In particular, for patients with decompensated cirrhosis, protease inhibitor-based regimens are contraindicated and should not be used. Although interferon-based regimens are not recommended for any HCV-infected patients when DAA regimens are available, they should especially be avoided in patients with decompensated cirrhosis because of the risk of exacerbated liver disease and death as well as very low rates of response. </p><p>Regimen selection by genotype is discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/16592.html" rel="external">"Management of chronic hepatitis C virus infection: Initial antiviral therapy in adults"</a> and  <a class="medical medical_review" href="/z/d/html/15795.html" rel="external">"Management of chronic hepatitis C virus infection: Antiviral retreatment following relapse in adults"</a>.)</p><p>The concept of using DAA regimens specifically for pretransplant treatment to prevent reinfection of the graft was first illustrated in an open-label study in which 61 patients on the liver transplant waitlist with Child A cirrhosis, biologic MELD score &lt;22, and hepatocellular carcinoma (who were thus listed with standard MELD exception points) were treated with <a class="drug drug_general" data-topicid="91794" href="/z/d/drug information/91794.html" rel="external">sofosbuvir</a> and weight-based <a class="drug drug_general" data-topicid="9860" href="/z/d/drug information/9860.html" rel="external">ribavirin</a> for up to 48 weeks prior to transplantation [<a href="#rid57">57</a>]. Of the 46 who underwent liver transplantation, 43 had undetectable viral loads at the time of transplantation, and 70 percent of them maintained a virologic response rate 12 weeks after transplantation. Recurrence (seen in 23 percent) was inversely related to the number of days that HCV RNA was undetectable prior to transplantation. This specific regimen is no longer recommended because of the more potent combinations available.</p><p>Subsequent studies have demonstrated efficacy and safety of other DAA combinations in patients with decompensated cirrhosis, including <a class="drug drug_general" data-topicid="97562" href="/z/d/drug information/97562.html" rel="external">ledipasvir-sofosbuvir</a> [<a href="#rid44">44,58,59</a>], <a class="drug drug_general" data-topicid="108951" href="/z/d/drug information/108951.html" rel="external">sofosbuvir-velpatasvir</a> [<a href="#rid46">46</a>], and <a class="drug drug_general" data-topicid="91794" href="/z/d/drug information/91794.html" rel="external">sofosbuvir</a> plus daclatasvir [<a href="#rid60">60</a>], each with or without <a class="drug drug_general" data-topicid="9860" href="/z/d/drug information/9860.html" rel="external">ribavirin</a> for 12 or 24 weeks. Sustained virologic response (SVR) rates are quite high (83 to 96 percent) among patients with CTP class B cirrhosis but appear to be lower in patients with more advanced Child-Pugh class C disease (56 to 87 percent).</p><p class="headingAnchor" id="H133461190"><span class="h1">USE OF GRAFTS FROM HCV-VIREMIC DONORS</span></p><p class="headingAnchor" id="H4245967559"><span class="h2">Outcomes</span></p><p class="headingAnchor" id="H2081715148"><span class="h3">In HCV-viremic recipients</span><span class="headingEndMark"> — </span>Given the high success rate of direct-acting antiviral (DAA) therapy and lack of sufficient liver allograft supply, use of livers from hepatitis C virus (HCV)-viremic donors for HCV-viremic recipients with subsequent DAA therapy is common. As an example, in the United States, the proportion of HCV-seropositive recipients who received a liver from a donor with chronic HCV infection increased from 7 to 17 percent between 2010 and 2015 [<a href="#rid61">61</a>]. </p><p>Use of livers from HCV-viremic donors had previously decreased wait time for HCV-viremic recipients, but since such organs are now more commonly allocated for recipients without HCV infection as well, the wait-time advantage has decreased. Nevertheless, livers from HCV-viremic donors could be of relatively high quality, as they are often of relatively young age; the average age of HCV-viremic donors declined from 47 to 35 years between 2012 and 2016, coincident with a rise in deceased donor organs available due to overdose-related death [<a href="#rid62">62</a>]. </p><p>Even prior to the widespread availability of DAAs, there did not appear to be a survival difference among HCV-viremic recipients who received a liver from an HCV-viremic versus nonviremic donor, although age and fibrosis stage of the donor were important considerations [<a href="#rid63">63-67</a>]. In one multicenter retrospective study with detailed biopsy data, overall survival was similar between patients who received livers from donors with or without HCV infection, but the risk of advanced fibrosis was significantly higher with grafts from HCV-viremic donors, especially from a donor older than 65 years [<a href="#rid65">65</a>]. When DAA therapy is given in the early post-transplant period, development of recurrent fibrosis is not a significant concern. </p><p class="headingAnchor" id="H4010459102"><span class="h3">In recipients without HCV infection</span><span class="headingEndMark"> — </span>Historically, organs from HCV-viremic donors were only used for recipients without HCV infection in urgent situations [<a href="#rid56">56</a>]. However, with the advent of highly effective DAA therapy, including pangenotypic regimens and effective salvage regimens for those who fail initial therapy, the use of livers from HCV-viremic donors for recipients without HCV infection followed by prompt DAA therapy has become more common [<a href="#rid68">68,69</a>]. In the United States, the number of such transplants increased 35-fold, from 8 in 2016 to 280 in 2019 [<a href="#rid70">70</a>].</p><p>Increasing evidence suggests that using organs from HCV-viremic donors is an overall effective and safe strategy in select HCV-negative recipients [<a href="#rid67">67</a>]. However, published cohorts describing this strategy for liver transplantation, specifically, have been relatively small: </p><p class="bulletIndent1"><span class="glyph">●</span>In one report of 10 HCV-negative recipients of livers from HCV-viremic donors, 100 percent achieved sustained virologic response (SVR) post-transplant with 12 to 24 weeks of therapy, with a median time from transplant to treatment of 43 days [<a href="#rid71">71</a>]. With a median 380 days of follow-up, there were no cases of graft loss.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In another series of 9 HCV-negative recipients of livers from HCV-viremic donors, all patients achieved SVR with 12 weeks of <a class="drug drug_general" data-topicid="114296" href="/z/d/drug information/114296.html" rel="external">glecaprevir-pibrentasvir</a>, which was initiated within five days of transplant [<a href="#rid72">72</a>]. There were no deaths after a median of 46 weeks of follow-up. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In another trial of HCV-negative recipients of livers (n = 13) or kidneys (n = 11), all achieved SVR with 12 weeks of <a class="drug drug_general" data-topicid="108951" href="/z/d/drug information/108951.html" rel="external">sofosbuvir-velpatasvir</a>, which was initiated once viremia was confirmed and the patient was clinically stable, a median of seven days after liver transplant [<a href="#rid73">73</a>].</p><p></p><p>In addition, in a retrospective study of deceased donor liver transplantations in the United States from 2008 to 2018, the two-year graft survival rates among HCV-negative recipients were similar whether they received a liver from an HCV-viremic donor (n = 87) or an HCV-nonviremic donor (n = 11,270, 86 versus 88 percent) [<a href="#rid67">67</a>]. One modeling study suggested that accepting any liver for transplantation (from either an HCV-viremic or nonviremic donor) rather than only those from nonviremic donors was associated with increased life expectancy among HCV-negative recipients with a Model for End-Stage Liver Disease (MELD) score ≥20 [<a href="#rid52">52</a>].</p><p>The feasibility of this approach has also been demonstrated among kidney transplant recipients. (See  <a class="medical medical_review" href="/z/d/html/7361.html" rel="external">"Hepatitis C virus infection in kidney donors", section on 'Use of kidneys from donors with HCV infection'</a>.)</p><p class="headingAnchor" id="H2532916970"><span class="h2">Treatment approach for recipients of HCV-viremic donors</span><span class="headingEndMark"> — </span>The risks and uncertainties of using livers from HCV-viremic donors followed by antiviral therapy should be discussed in detail with potential recipients, and adequate access to DAA therapy following transplantation should be ensured [<a href="#rid74">74-76</a>]. The optimal approach to timing of antiviral treatment and regimen selection for recipients of livers from HCV-viremic donors is uncertain. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Regimen selection</strong> – In general, we agree with joint guidelines from the American Association for the Study of Liver Diseases (AASLD) and Infectious Diseases Society of America (IDSA) that recommend pangenotypic regimens (<a class="drug drug_general" data-topicid="114296" href="/z/d/drug information/114296.html" rel="external">glecaprevir-pibrentasvir</a> or <a class="drug drug_general" data-topicid="108951" href="/z/d/drug information/108951.html" rel="external">sofosbuvir-velpatasvir</a>) as first-line treatment [<a href="#rid69">69</a>]. In contrast with other organs from HCV-viremic donors, short durations of HCV therapy should not be used in recipients of livers from HCV-viremic donors because of the large reservoir of HCV in the transplanted organ. The specific regimens are discussed below. (See <a class="local">'Post-transplant regimen selection'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Timing of treatment</strong> – We also agree with guidelines that suggest early treatment, defined as starting within the first month after transplant, and preferably within the first week, once the patient is clinically stable [<a href="#rid77">77</a>]. Randomized trials have not been performed to support a particular timeline. However, in most published reports of using livers from HCV-viremic donors, antiviral treatment is generally initiated once the recipient has confirmed viremia following transplant and has achieved clinical stability; in some cases, these criteria were met within a week of transplantation [<a href="#rid71">71-73</a>]. Early treatment is favored because of the potential risk of severe complications, such as fibrosing cholestatic HCV, a severe form of recurrent HCV. (See <a class="local">'Progression of liver disease post-transplant'</a> above.)</p><p></p><p>The limited evidence supporting this approach is discussed elsewhere (see <a class="local">'In recipients without HCV infection'</a> above). The risk of immunologic complications (eg, rejection) in recipients of livers from HCV-viremic donors treated with DAA therapy requires further study [<a href="#rid69">69,73</a>].</p><p class="headingAnchor" id="H13"><span class="h1">EVALUATION OF HCV INFECTION POST-TRANSPLANT</span></p><p class="headingAnchor" id="H2793536989"><span class="h2">Assessment of HCV recurrence</span><span class="headingEndMark"> — </span>Hepatitis C virus (HCV) reinfection of the graft is detected by testing for HCV RNA. While there is no clear recommendation in terms of timing of this testing, we recommend testing viral load and confirming the HCV genotype when the patient is stable enough post-transplant to consider initiating antiviral therapy. (See <a class="local">'Timing'</a> below.)</p><p class="headingAnchor" id="H2732727017"><span class="h2">Staging of recurrent disease</span><span class="headingEndMark"> — </span>Stage of liver disease (ie, presence or absence of significant fibrosis or cirrhosis) may inform antiviral regimen selection (see <a class="local">'Post-transplant regimen selection'</a> below) and other management considerations. For routine assessment of post-treatment fibrosis stage, noninvasive measures of fibrosis are adequate, as in the non-transplant setting. We use transient elastography, since serum markers of fibrosis have not been well studied or validated in the post-transplant setting.</p><p>Elastography, whether done as vibration-controlled transient elastography (VCTE; eg, FibroScan), ultrasound-based shear wave, or magnetic resonance elastography, all appear to be relatively accurate measure of fibrosis stage in transplant patients. For example, in a systematic review that pooled five studies of patients with recurrent HCV infection post-transplant, the sensitivity and specificity of ultrasound-based elastography for significant fibrosis were both 83 percent and for cirrhosis were 98 and 84 percent, respectively [<a href="#rid78">78</a>]. (See  <a class="medical medical_review" href="/z/d/html/96717.html" rel="external">"Noninvasive assessment of hepatic fibrosis: Ultrasound-based elastography"</a>.)</p><p>Serum markers have also been evaluated in the transplant population, although do not appear to be as accurate as ultrasound-based elastography [<a href="#rid79">79,80</a>]. (See  <a class="medical medical_review" href="/z/d/html/1239.html" rel="external">"Noninvasive assessment of hepatic fibrosis: Overview of serologic tests and imaging examinations"</a>.)</p><p>Prior to the availability of effective post-transplant treatment, many centers performed routine liver biopsies to risk stratify patients for treatment. This practice is now uncommon, and liver biopsy is generally reserved for patients with evidence of liver injury (eg, aminotransferase elevation) in whom other causes, including acute T cell-mediated (cellular) rejection (TCMR), are a concern. After the early post-transplant period (ie, three to six months), however, rejection is uncommon, and antiviral treatment for HCV infection may be undertaken empirically in the setting of abnormal liver biochemical tests instead of pursuing biopsy, since the likelihood that HCV is the cause is extremely high. (See  <a class="medical medical_review" href="/z/d/html/4587.html" rel="external">"Liver transplantation in adults: Clinical manifestations and diagnosis of acute T-cell mediated (cellular) rejection of the liver allograft"</a>.)</p><p>Biopsy findings related to HCV infection are typically mild and nonspecific, particularly with early recurrence. They include periportal inflammation, lobular ballooning of hepatocytes, acidophilic bodies, or lobular apoptosis. Some of these features are also seen in acute TCMR. Particular features supportive of recurrent HCV are lobular activity, interface hepatitis, piecemeal necrosis, and lymphocyte predominance or lymphoid follicles. Features that are more suggestive of rejection include a mixed cellular infiltrate (eosinophils, polymorphonuclear cells, and lymphocytes) confined to the portal triad, bile duct damage, and endotheliitis. Nevertheless, differentiating rejection in the setting of HCV infection from HCV infection alone can be difficult on pathologic grounds.</p><p class="headingAnchor" id="H1415742686"><span class="h1">POST-TRANSPLANT ANTIVIRAL THERAPY</span></p><p class="headingAnchor" id="H2560812457"><span class="h2">Benefits</span><span class="headingEndMark"> — </span>All liver transplant recipients with HCV viremia should be treated. </p><p>Patients who achieve sustained virologic response (SVR) with treatment post-transplant have lower rates of liver fibrosis progression and lower mortality rates compared to those who fail therapy [<a href="#rid81">81,82</a>]. Accordingly, the short-term post-transplant survival for HCV-associated liver disease has increased with increased use of highly effective direct-acting antiviral (DAA) therapy [<a href="#rid83">83,84</a>]. As an example, in a report of the United Network for Organ Sharing (UNOS) database, one-year post-transplant survival rates from the "DAA era" (transplanted in 2014 and 2015) were higher than from the "pre-DAA era" (transplanted in 2011 and 2012) (91.9 versus 89.8 percent) [<a href="#rid83">83</a>]. In addition, in a multivariable analysis, transplantation during the DAA era was associated with a 34 percent reduction in one-year post-liver transplant patient mortality, and post-transplant survival was similar or better among patients transplanted for HCV-associated liver disease compared with other indications.</p><p>The general benefits of SVR are discussed in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/15832.html" rel="external">"Patient evaluation and selection for antiviral therapy for chronic hepatitis C virus infection", section on 'Benefits of treatment'</a>.)</p><p>Although studies evaluating the impact of interferon-based therapy had failed to show differences in outcomes with early antiviral therapy post-transplant compared with no treatment or treatment only after the development of significant fibrosis [<a href="#rid85">85,86</a>], this is likely related to the low rates of SVR achieved with such regimens. </p><p class="headingAnchor" id="H2049099584"><span class="h2">Timing</span><span class="headingEndMark"> — </span>The optimal timing of post-transplant treatment is uncertain, and the decision must be made on an individual basis. Our approach is to treat patients as soon as possible once they are clinically stable following transplant. In particular, we prioritize treatment within the first month to prevent the risks of complications including fibrosing cholestatic HCV. (See <a class="local">'Progression of liver disease post-transplant'</a> above.) </p><p class="headingAnchor" id="H1532143969"><span class="h2">Post-transplant regimen selection</span><span class="headingEndMark"> — </span>Antiviral therapy should be administered at centers with experience in managing post-transplantation patients. DAA combination options for liver transplant recipients are more limited than in the general population due to drug-drug interactions (see <a class="local">'Interactions with immunosuppressive agents'</a> below), and fewer regimens have been formally studied in post-transplant patients. Details on the optimal regimen choice and durations are also evolving, as data informing these remain relatively limited. </p><p>As in the non-transplant setting, regimen options depend on the HCV genotype, the presence of cirrhosis, drug-drug interactions, and comorbidities. Overall, our suggestions are generally consistent with recommendations in the joint <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.hcvguidelines.org%2F&amp;token=sL%2Bp%2BgWoM5K8OZ3TcR7z2aLRyWCGNBK9vbXZNzy9A7wOhWa41Lo4fh2xvvlb%2BhyX&amp;TOPIC_ID=4583" target="_blank">guidelines</a> from the American Association for the Study of Liver Diseases and the Infectious Diseases Society of America (AASLD/IDSA) [<a href="#rid77">77</a>]. Selection among the options for each patient population should also be informed by the potential for drug interactions, in particular with immunosuppressant medications. (See <a class="local">'Patients without decompensated cirrhosis'</a> below and <a class="local">'Patients with decompensated cirrhosis'</a> below.)</p><p>The doses for the individual DAA agents used post-transplant do not differ from those in the non-transplant setting and are discussed elsewhere (see  <a class="medical medical_review" href="/z/d/html/93242.html" rel="external">"Direct-acting antivirals for the treatment of hepatitis C virus infection"</a>). When <a class="drug drug_general" data-topicid="9860" href="/z/d/drug information/9860.html" rel="external">ribavirin</a> is used, the doses will be specified for the particular regimen (either low dose starting at 600 mg daily and increasing as tolerated or weight-based dosing at 1000 mg daily for patients &lt;75 kg or 1200 mg daily for patients ≥75 kg). The dosing of ribavirin should also take into account the patient's creatinine clearance and hemoglobin level.</p><p>Peginterferon-based regimens are not recommended because of the toxicity, the overall poor response rates (in the absence of a DAA), and the risk of rejection.</p><p class="headingAnchor" id="H3242594314"><span class="h3">Patients without decompensated cirrhosis</span><span class="headingEndMark"> — </span>For HCV-infected liver transplant recipients who do not have cirrhosis or have compensated cirrhosis, we suggest:</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="114296" href="/z/d/drug information/114296.html" rel="external">Glecaprevir-pibrentasvir</a> for 12 weeks</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="108951" href="/z/d/drug information/108951.html" rel="external">Sofosbuvir-velpatasvir</a> for 12 weeks </p><p></p><p>These are preferred options for any genotype. For patients with genotype 1, 4, 5, or 6 infection, <a class="drug drug_general" data-topicid="97562" href="/z/d/drug information/97562.html" rel="external">ledipasvir-sofosbuvir</a> plus weight-based <a class="drug drug_general" data-topicid="9860" href="/z/d/drug information/9860.html" rel="external">ribavirin</a> (1000 mg daily for patients &lt;75 kg or 1200 mg daily for patients ≥75 kg) for 12 weeks is an alternative option. </p><p>These regimens have well-documented safety and efficacy in the post-transplant population.</p><p>For patients without cirrhosis:</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="114296" href="/z/d/drug information/114296.html" rel="external">Glecaprevir-pibrentasvir</a>: In an open-label trial of 100 transplant recipients (80 were liver) with HCV infection of all genotypes and without cirrhosis, glecaprevir-pibrentasvir resulted in an SVR rate of 98 percent [<a href="#rid87">87</a>]. High SVR rates were observed in both treatment-naïve and interferon-experienced patients. The regimen was well tolerated; there was one mild liver transplant rejection, which was thought unrelated to antiviral therapy. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="108951" href="/z/d/drug information/108951.html" rel="external">Sofosbuvir-velpatasvir</a>: In an open-label trial that included 65 liver transplant recipients with genotypes 1 through 4 infection and without cirrhosis, sofosbuvir-velpatasvir resulted in an SVR rate of 97 percent [<a href="#rid88">88</a>]. No patients experienced acute rejection, and the few serious adverse events were deemed unrelated to therapy. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="97562" href="/z/d/drug information/97562.html" rel="external">Ledipasvir-sofosbuvir</a><strong> plus </strong><a class="drug drug_general" data-topicid="9860" href="/z/d/drug information/9860.html" rel="external">ribavirin</a>: In two large trials (SOLAR-1 and SOLAR-2, which respectively included 111 and 101 genotype 1- or 4-infected patients without cirrhosis), ledipasvir-sofosbuvir plus weight-based ribavirin for 12 weeks resulted in SVR rates in 96 and 93 percent [<a href="#rid44">44,58</a>]. The regimen was well tolerated. Large observational studies have also supported the high efficacy and safety of ledipasvir-sofosbuvir in the liver transplant population; in these studies, ribavirin was not associated with a higher SVR rate, but it is unknown if unmeasured confounders impact the comparison [<a href="#rid89">89-91</a>]. Graft rejection was rare in these studies. Efficacy in genotypes 5 and 6 is extrapolated from studies in the non-transplant population. This regimen is not used for genotype 2 or 3. </p><p></p><p class="bulletIndent1">One large observational study has suggested that <a class="drug drug_general" data-topicid="9860" href="/z/d/drug information/9860.html" rel="external">ribavirin</a> is not necessary in this population. Among approximately 500 post-transplant patients who were treated with <a class="drug drug_general" data-topicid="91794" href="/z/d/drug information/91794.html" rel="external">sofosbuvir</a> plus an NS5A inhibitor (ledipasvir or daclatasvir) with or without ribavirin for 12 to 24 weeks, SVR rates were 95 to 98 percent among the approximately 400 who did not receive ribavirin and were not different with the addition of ribavirin [<a href="#rid92">92</a>]. Nevertheless, pending further data, we continue to use ribavirin, if tolerated, with sofosbuvir-ledipasvir and sofosbuvir plus daclatasvir, since this is how the regimens were evaluated in the above prospective trials. </p><p></p><p>For patients with compensated cirrhosis:</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="108951" href="/z/d/drug information/108951.html" rel="external">Sofosbuvir-velpatasvir</a>: In an open-label trial that included 14 liver transplant recipients with genotypes 1 through 4 infection and cirrhosis, sofosbuvir-velpatasvir resulted in an SVR rate of 93 percent [<a href="#rid88">88</a>]. No patients experienced acute rejection, and the few serious adverse events were deemed unrelated to therapy. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="97562" href="/z/d/drug information/97562.html" rel="external">Ledipasvir-sofosbuvir</a><strong> plus </strong><a class="drug drug_general" data-topicid="9860" href="/z/d/drug information/9860.html" rel="external">ribavirin</a>: In two large trials (SOLAR-1 and SOLAR-2, which respectively included 51 and 58 genotype 1- or 4-infected patients with compensated cirrhosis [Child-Pugh class A]), ledipasvir-sofosbuvir plus weight-based ribavirin for 12 weeks resulted in SVR rates in 96 and 100 percent [<a href="#rid44">44,58</a>]. The regimen was well tolerated. As in patients without cirrhosis, large observational studies have also supported the high efficacy and safety of ledipasvir-sofosbuvir in the liver transplant population [<a href="#rid89">89,90</a>]. Graft rejection was rare in these studies. Efficacy in genotypes 5 and 6 is extrapolated from studies in the non-transplant population. This regimen is not used for genotypes 2 or 3. </p><p></p><p class="bulletIndent1">One large observational study suggested that <a class="drug drug_general" data-topicid="9860" href="/z/d/drug information/9860.html" rel="external">ribavirin</a> was not associated with improved SVR rates when added to <a class="drug drug_general" data-topicid="91794" href="/z/d/drug information/91794.html" rel="external">sofosbuvir</a> plus an NS5A inhibitor (ledipasvir or daclatasvir), but the majority of patients in that study did not have cirrhosis [<a href="#rid92">92</a>]. We continue to use ribavirin, if tolerated, with sofosbuvir-ledipasvir and sofosbuvir plus daclatasvir, since this is how the regimens were evaluated in the above prospective trials, but not with <a class="drug drug_general" data-topicid="108951" href="/z/d/drug information/108951.html" rel="external">sofosbuvir-velpatasvir</a> (or <a class="drug drug_general" data-topicid="114296" href="/z/d/drug information/114296.html" rel="external">glecaprevir-pibrentasvir</a>). </p><p></p><p class="headingAnchor" id="H3109069394"><span class="h3">Patients with decompensated cirrhosis</span><span class="headingEndMark"> — </span>Antiviral treatment of post-transplant patients with decompensated cirrhosis (ascites, hepatic encephalopathy, or gastroesophageal variceal hemorrhage; Child-Pugh class B or C) should only be undertaken by or in close consultation with an expert in the management of such patients. The main options for treatment-naïve patients include <a class="drug drug_general" data-topicid="108951" href="/z/d/drug information/108951.html" rel="external">sofosbuvir-velpatasvir</a> plus low-dose <a class="drug drug_general" data-topicid="9860" href="/z/d/drug information/9860.html" rel="external">ribavirin</a> (600 mg daily with increase to 1000 mg as tolerated) for 12 weeks or, for patients with genotypes 1, 4, 5, and 6 infection, <a class="drug drug_general" data-topicid="97562" href="/z/d/drug information/97562.html" rel="external">ledipasvir-sofosbuvir</a> plus low-dose ribavirin (600 mg daily with increase to 1000 mg as tolerated) for 12 weeks.</p><p>Several antiviral regimens that contain a protease inhibitor are contraindicated in patients with Child-Pugh classes B and C cirrhosis. These include <a class="drug drug_general" data-topicid="114296" href="/z/d/drug information/114296.html" rel="external">glecaprevir-pibrentasvir</a>, <a class="drug drug_general" data-topicid="106574" href="/z/d/drug information/106574.html" rel="external">elbasvir-grazoprevir</a>, and <a class="drug drug_general" data-topicid="114088" href="/z/d/drug information/114088.html" rel="external">sofosbuvir-velpatasvir-voxilaprevir</a>. </p><p class="headingAnchor" id="H3385121860"><span class="h3">Interactions with immunosuppressive agents</span><span class="headingEndMark"> — </span>The immunosuppressive regimen that an individual patient is on may limit the selection of the antiviral agent or need to be modified. </p><p>In general, DAA regimens that contain a protease inhibitor have the potential to increase drug levels of calcineurin inhibitors (<a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a> and, to a lesser extent, <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">tacrolimus</a>) and inhibitors of mammalian target of rapamycin (mTOR; <a class="drug drug_general" data-topicid="10329" href="/z/d/drug information/10329.html" rel="external">sirolimus</a> and <a class="drug drug_general" data-topicid="9078" href="/z/d/drug information/9078.html" rel="external">everolimus</a>); some combinations are not recommended, whereas other combinations warrant close monitoring of immunosuppressive drug levels. Specific potential drug interactions are listed in the table  (<a class="graphic graphic_table graphicRef118768" href="/z/d/graphic/118768.html" rel="external">table 1</a>). Drug interactions can also be checked through the <a class="external" href="/drug-interactions">drug interactions program</a> included with UpToDate. </p><p class="headingAnchor" id="H2384053499"><span class="h1">INVESTIGATIONAL THERAPIES</span><span class="headingEndMark"> — </span>Preliminary evidence suggests that antiviral treatment initiated around the time of transplantation can prevent reinfection of the new graft. In an open-label study, 16 patients with chronic HCV undergoing their first liver transplantation received a single dose of <a class="drug drug_general" data-topicid="97562" href="/z/d/drug information/97562.html" rel="external">ledipasvir-sofosbuvir</a> the day they arrived at the hospital for transplantation and once daily for four weeks postoperatively [<a href="#rid93">93</a>]. The sustained virologic response rate 12 weeks after completion of treatment was 88 percent (95% CI 62-98). In one patient with a virologic relapse by four weeks post-treatment, a sustained virologic response was achieved after retreatment with 12 weeks of ledipasvir–<a class="drug drug_general" data-topicid="91794" href="/z/d/drug information/91794.html" rel="external">sofosbuvir</a>. Additional studies are needed to evaluate this approach. </p><p>Unlike hepatitis B virus, no effective immunoglobulin prophylaxis agents are approved to prevent reinfection of the graft at the time of transplantation. Further, such strategies are not needed given the high success with direct-acting antivirals for HCV with a finite duration of therapy. </p><p class="headingAnchor" id="H1052735548"><span class="h1">RETRANSPLANTATION</span><span class="headingEndMark"> — </span>Disease recurrence may ultimately lead to graft failure and the need for retransplantation. Indications and contraindications for retransplantation remain unclear, and practices vary widely among institutions.</p><p>Historically, the prognosis for such patients has been poor (similar to retransplantation for other indications) [<a href="#rid94">94-102</a>]. This was illustrated in a multicenter study that compared survival following retransplantation in patients with recurrent HCV with survival following retransplantation for other disorders [<a href="#rid103">103</a>]. The one-year (69 versus 73 percent) and three-year (49 versus 55 percent) survival rates were similar in the HCV and non-HCV groups. Model for End-Stage Liver Disease (MELD) scores were not predictive of survival. Many patients were not considered eligible for retransplantation and died from recurrent disease.</p><p>With the rapidly changing field of HCV treatment and likely improved safety and efficacy of pre- and post-transplant HCV treatment, transplantation outcomes in patients with advanced recurrent disease are likely to improve, and the need for retransplantation in this setting will hopefully diminish over time.</p><p class="headingAnchor" id="H53292917"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/113623.html" rel="external">"Society guideline links: Hepatitis C infection in solid organ transplant candidates and recipients"</a> and  <a class="medical medical_society_guidelines" href="/z/d/html/113977.html" rel="external">"Society guideline links: Liver transplantation"</a>.)</p><p class="headingAnchor" id="H2429837673"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Impact of DAA therapy </strong>–<strong> </strong>Hepatitis C virus (HCV)-associated cirrhosis has been a common indication for liver transplantation, but the introduction of well-tolerated, highly effective direct-acting antiviral (DAA) therapy for HCV is reducing the need for liver transplantation in such patients and has revolutionized the approach to management of transplant candidates and recipients. Successful antiviral treatment of liver transplant recipients with HCV infection reduces progression of liver fibrosis and mortality post-transplant. (See <a class="local">'Introduction'</a> above and <a class="local">'Post-transplant clinical course'</a> above and <a class="local">'Benefits'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Deciding to treat before or after transplant </strong>–<strong> </strong>If not treated pretransplant, HCV reinfection of the transplanted liver is near universal and can be a major cause of graft failure without effective antiviral treatment post-transplant. However, pretransplant antiviral therapy is not the optimal treatment strategy for certain patients, and the decision to treat before or after transplant should be individualized, taking into account the short-term prognosis, the likelihood of meaningful response to therapy, access to transplant, and other comorbidities. (See <a class="local">'Considerations'</a> above.)</p><p></p><p class="bulletIndent1">In general, we suggest pretransplant antiviral therapy for patients with Child-Pugh score A or B and Model for End-Stage Liver Disease (MELD) score &lt;20 or access to transplant through living donation or MELD exception points (when the expected waiting time is less than one year) (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). We suggest deferring antiviral therapy until after transplantation for those with severe portal hypertension or high MELD (eg, MELD &gt;27) or with decompensated cirrhosis and severe renal impairment (estimated glomerular filtration rate [eGFR] &lt;30 mL/min) (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). Data informing the optimal approach are limited. (See <a class="local">'Approach'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Regimen selection for pretransplant antiviral treatment </strong>–<strong> </strong>Pretransplant regimen selection depends on genotype, presence of cirrhosis, degree of hepatic dysfunction, treatment history, and comorbidities. In particular, for patients with decompensated cirrhosis, protease inhibitor-based regimens are contraindicated. Regimen selection by genotype is discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/16592.html" rel="external">"Management of chronic hepatitis C virus infection: Initial antiviral therapy in adults"</a> and  <a class="medical medical_review" href="/z/d/html/15795.html" rel="external">"Management of chronic hepatitis C virus infection: Antiviral retreatment following relapse in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Use of livers from HCV-viremic donors</strong> – With the advent of highly effective antiviral therapy, including pangenotypic regimens and effective salvage regimens for those who fail initial therapy, allocating livers from HCV-viremic donors for HCV-negative recipients, in addition to HCV-viremic recipients, with subsequent DAA therapy has become more common. Limited evidence from small cohorts suggest this is a safe and effective strategy. (See <a class="local">'Use of grafts from HCV-viremic donors'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Post-transplant evaluation for HCV </strong>– The diagnosis of recurrent HCV infection is based upon the detection of HCV RNA. We also perform genotype testing. Among patients with prolonged post-transplant viremia, we use transient elastography to assess fibrosis stage. (See <a class="local">'Evaluation of HCV infection post-transplant'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Post-transplant antiviral treatment </strong>–<strong> </strong>We recommend that all liver transplant recipients with HCV viremia undergo antiviral therapy (<a class="grade" href="https:///uptodate/show/grade_2" rel="external">Grade 1B</a>). Antiviral therapy should be administered at centers with experience in managing post-transplantation patients. We aim to initiate antiviral therapy as soon as possible once the patient is clinically stable following transplant, ideally within the first month. </p><p></p><p class="bulletIndent1">There are fewer data on the use of combination DAA regimens in liver transplant recipients than in the general population. Regimen selection depends on genotype and presence of decompensated cirrhosis. (See <a class="local">'Post-transplant regimen selection'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients without cirrhosis or with compensated cirrhosis, we suggest <a class="drug drug_general" data-topicid="114296" href="/z/d/drug information/114296.html" rel="external">glecaprevir-pibrentasvir</a> for 12 weeks or <a class="drug drug_general" data-topicid="108951" href="/z/d/drug information/108951.html" rel="external">sofosbuvir-velpatasvir</a> for 12 weeks (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). For patients with genotype 1, 4, 5, or 6 infection, <a class="drug drug_general" data-topicid="97562" href="/z/d/drug information/97562.html" rel="external">ledipasvir-sofosbuvir</a> plus weight-based <a class="drug drug_general" data-topicid="9860" href="/z/d/drug information/9860.html" rel="external">ribavirin</a> for 12 weeks is an alternative option. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Antiviral treatment of post-transplant patients with decompensated cirrhosis (ascites, hepatic encephalopathy, or gastroesophageal variceal hemorrhage; Child-Pugh class B or C) should only be undertaken by or in close consultation with an expert in the management of such patients. Regimens containing protease inhibitors (eg, <a class="drug drug_general" data-topicid="114296" href="/z/d/drug information/114296.html" rel="external">glecaprevir-pibrentasvir</a>) should not be used in decompensated cirrhosis.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The immunosuppressive regimen that an individual patient is on may limit the selection of the antiviral agent or need to be modified during antiviral therapy  (<a class="graphic graphic_table graphicRef118768" href="/z/d/graphic/118768.html" rel="external">table 1</a>). </p></div><div class="headingAnchor" id="references"><ol id="reference"><li class="breakAll">http://www.unos.org/ (Accessed on March 27, 2007).</li><li><a class="nounderline abstract_t">Verna EC, Brown RS Jr. Hepatitis C virus and liver transplantation. Clin Liver Dis 2006; 10:919.</a></li><li><a class="nounderline abstract_t">Cholankeril G, Ahmed A. Alcoholic Liver Disease Replaces Hepatitis C Virus Infection as the Leading Indication for Liver Transplantation in the United States. Clin Gastroenterol Hepatol 2018; 16:1356.</a></li><li><a class="nounderline abstract_t">Wright TL, Donegan E, Hsu HH, et al. Recurrent and acquired hepatitis C viral infection in liver transplant recipients. Gastroenterology 1992; 103:317.</a></li><li><a class="nounderline abstract_t">Dickson RC, Caldwell SH, Ishitani MB, et al. Clinical and histologic patterns of early graft failure due to recurrent hepatitis C in four patients after liver transplantation. Transplantation 1996; 61:701.</a></li><li><a class="nounderline abstract_t">Garcia-Retortillo M, Forns X, Feliu A, et al. Hepatitis C virus kinetics during and immediately after liver transplantation. Hepatology 2002; 35:680.</a></li><li><a class="nounderline abstract_t">Gane EJ, Naoumov NV, Qian KP, et al. A longitudinal analysis of hepatitis C virus replication following liver transplantation. Gastroenterology 1996; 110:167.</a></li><li><a class="nounderline abstract_t">Féray C, Samuel D, Thiers V, et al. Reinfection of liver graft by hepatitis C virus after liver transplantation. J Clin Invest 1992; 89:1361.</a></li><li><a class="nounderline abstract_t">Berenguer M. Natural history of recurrent hepatitis C. Liver Transpl 2002; 8:S14.</a></li><li><a class="nounderline abstract_t">Gane EJ, Portmann BC, Naoumov NV, et al. Long-term outcome of hepatitis C infection after liver transplantation. N Engl J Med 1996; 334:815.</a></li><li><a class="nounderline abstract_t">Araya V, Rakela J, Wright T. Hepatitis C after orthotopic liver transplantation. Gastroenterology 1997; 112:575.</a></li><li><a class="nounderline abstract_t">Féray C, Caccamo L, Alexander GJ, et al. European collaborative study on factors influencing outcome after liver transplantation for hepatitis C. European Concerted Action on Viral Hepatitis (EUROHEP) Group. Gastroenterology 1999; 117:619.</a></li><li><a class="nounderline abstract_t">Pessoa MG, Bzowej N, Berenguer M, et al. Evolution of hepatitis C virus quasispecies in patients with severe cholestatic hepatitis after liver transplantation. Hepatology 1999; 30:1513.</a></li><li><a class="nounderline abstract_t">Rosen HR, Hinrichs DJ, Gretch DR, et al. Association of multispecific CD4(+) response to hepatitis C and severity of recurrence after liver transplantation. Gastroenterology 1999; 117:926.</a></li><li><a class="nounderline abstract_t">Nair S, Eustace J, Thuluvath PJ. Effect of race on outcome of orthotopic liver transplantation: a cohort study. Lancet 2002; 359:287.</a></li><li><a class="nounderline abstract_t">Yilmaz N, Shiffman ML, Stravitz RT, et al. A prospective evaluation of fibrosis progression in patients with recurrent hepatitis C virus following liver transplantation. Liver Transpl 2007; 13:975.</a></li><li><a class="nounderline abstract_t">Belli LS, Burroughs AK, Burra P, et al. Liver transplantation for HCV cirrhosis: improved survival in recent years and increased severity of recurrent disease in female recipients: results of a long term retrospective study. Liver Transpl 2007; 13:733.</a></li><li><a class="nounderline abstract_t">Garcia-Retortillo M, Forns X, Llovet JM, et al. Hepatitis C recurrence is more severe after living donor compared to cadaveric liver transplantation. Hepatology 2004; 40:699.</a></li><li><a class="nounderline abstract_t">Shiffman ML, Stravitz RT, Contos MJ, et al. Histologic recurrence of chronic hepatitis C virus in patients after living donor and deceased donor liver transplantation. Liver Transpl 2004; 10:1248.</a></li><li><a class="nounderline abstract_t">Berenguer M, Crippin J, Gish R, et al. A model to predict severe HCV-related disease following liver transplantation. Hepatology 2003; 38:34.</a></li><li><a class="nounderline abstract_t">Féray C, Gigou M, Samuel D, et al. The course of hepatitis C virus infection after liver transplantation. Hepatology 1994; 20:1137.</a></li><li><a class="nounderline abstract_t">Casavilla FA, Rakela J, Kapur S, et al. Clinical outcome of patients infected with hepatitis C virus infection on survival after primary liver transplantation under tacrolimus. Liver Transpl Surg 1998; 4:448.</a></li><li><a class="nounderline abstract_t">Neumann UP, Berg T, Bahra M, et al. Fibrosis progression after liver transplantation in patients with recurrent hepatitis C. J Hepatol 2004; 41:830.</a></li><li><a class="nounderline abstract_t">Blasco A, Forns X, Carrión JA, et al. Hepatic venous pressure gradient identifies patients at risk of severe hepatitis C recurrence after liver transplantation. Hepatology 2006; 43:492.</a></li><li><a class="nounderline abstract_t">Gawrieh S, Papouchado BG, Burgart LJ, et al. Early hepatic stellate cell activation predicts severe hepatitis C recurrence after liver transplantation. Liver Transpl 2005; 11:1207.</a></li><li><a class="nounderline abstract_t">Berenguer M. What determines the natural history of recurrent hepatitis C after liver transplantation? J Hepatol 2005; 42:448.</a></li><li><a class="nounderline abstract_t">Féray C, Gigou M, Samuel D, et al. Influence of the genotypes of hepatitis C virus on the severity of recurrent liver disease after liver transplantation. Gastroenterology 1995; 108:1088.</a></li><li><a class="nounderline abstract_t">Gordon SC, Bayati N, Silverman AL. Clinical outcome of hepatitis C as a function of mode of transmission. Hepatology 1998; 28:562.</a></li><li><a class="nounderline abstract_t">Gordon FD, Poterucha JJ, Germer J, et al. Relationship between hepatitis C genotype and severity of recurrent hepatitis C after liver transplantation. Transplantation 1997; 63:1419.</a></li><li><a class="nounderline abstract_t">Zhou S, Terrault NA, Ferrell L, et al. Severity of liver disease in liver transplantation recipients with hepatitis C virus infection: relationship to genotype and level of viremia. Hepatology 1996; 24:1041.</a></li><li><a class="nounderline abstract_t">Charlton M, Seaberg E, Wiesner R, et al. Predictors of patient and graft survival following liver transplantation for hepatitis C. Hepatology 1998; 28:823.</a></li><li><a class="nounderline abstract_t">Vargas HE, Laskus T, Wang LF, et al. The influence of hepatitis C virus genotypes on the outcome of liver transplantation. Liver Transpl Surg 1998; 4:22.</a></li><li><a class="nounderline abstract_t">Sreekumar R, Gonzalez-Koch A, Maor-Kendler Y, et al. Early identification of recipients with progressive histologic recurrence of hepatitis C after liver transplantation. Hepatology 2000; 32:1125.</a></li><li><a class="nounderline abstract_t">Cameron AM, Ghobrial RM, Hiatt JR, et al. Effect of nonviral factors on hepatitis C recurrence after liver transplantation. Ann Surg 2006; 244:563.</a></li><li><a class="nounderline abstract_t">Faber W, Seehofer D, Puhl G, et al. Donor age does not influence 12-month outcome after orthotopic liver transplantation. Transplant Proc 2011; 43:3789.</a></li><li><a class="nounderline abstract_t">Zhao Y, Lo CM, Liu CL, Fan ST. Use of elderly donors (&gt; 60 years) for liver transplantation. Asian J Surg 2004; 27:114.</a></li><li><a class="nounderline abstract_t">Lake JR, Shorr JS, Steffen BJ, et al. Differential effects of donor age in liver transplant recipients infected with hepatitis B, hepatitis C and without viral hepatitis. Am J Transplant 2005; 5:549.</a></li><li><a class="nounderline abstract_t">Berenguer M, Prieto M, San Juan F, et al. Contribution of donor age to the recent decrease in patient survival among HCV-infected liver transplant recipients. Hepatology 2002; 36:202.</a></li><li><a class="nounderline abstract_t">Burak KW, Kremers WK, Batts KP, et al. Impact of cytomegalovirus infection, year of transplantation, and donor age on outcomes after liver transplantation for hepatitis C. Liver Transpl 2002; 8:362.</a></li><li><a class="nounderline abstract_t">Thuluvath PJ, Guidinger MK, Fung JJ, et al. Liver transplantation in the United States, 1999-2008. Am J Transplant 2010; 10:1003.</a></li><li><a class="nounderline abstract_t">Böker KH, Dalley G, Bahr MJ, et al. Long-term outcome of hepatitis C virus infection after liver transplantation. Hepatology 1997; 25:203.</a></li><li><a class="nounderline abstract_t">Charlton M, Ruppert K, Belle SH, et al. Long-term results and modeling to predict outcomes in recipients with HCV infection: results of the NIDDK liver transplantation database. Liver Transpl 2004; 10:1120.</a></li><li><a class="nounderline abstract_t">Forman LM, Lewis JD, Berlin JA, et al. The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology 2002; 122:889.</a></li><li><a class="nounderline abstract_t">Charlton M, Everson GT, Flamm SL, et al. Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver Disease. Gastroenterology 2015; 149:649.</a></li><li><a class="nounderline abstract_t">Bunchorntavakul C, Reddy KR. Treat chronic hepatitis C virus infection in decompensated cirrhosis - pre- or post-liver transplantation? the ironic conundrum in the era of effective and well-tolerated therapy. J Viral Hepat 2016; 23:408.</a></li><li><a class="nounderline abstract_t">Curry MP, O'Leary JG, Bzowej N, et al. Sofosbuvir and Velpatasvir for HCV in Patients with Decompensated Cirrhosis. N Engl J Med 2015; 373:2618.</a></li><li><a class="nounderline abstract_t">Belli LS, Berenguer M, Cortesi PA, et al. Delisting of liver transplant candidates with chronic hepatitis C after viral eradication: A European study. J Hepatol 2016; 65:524.</a></li><li><a class="nounderline abstract_t">Martini S, Sacco M, Strona S, et al. Impact of viral eradication with sofosbuvir-based therapy on the outcome of post-transplant hepatitis C with severe fibrosis. Liver Int 2017; 37:62.</a></li><li><a class="nounderline abstract_t">El-Sherif O, Jiang ZG, Tapper EB, et al. Baseline Factors Associated With Improvements in Decompensated Cirrhosis After Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection. Gastroenterology 2018; 154:2111.</a></li><li><a class="nounderline abstract_t">Pascasio JM, Vinaixa C, Ferrer MT, et al. Clinical outcomes of patients undergoing antiviral therapy while awaiting liver transplantation. J Hepatol 2017; 67:1168.</a></li><li><a class="nounderline abstract_t">Verna EC, Morelli G, Terrault NA, et al. DAA therapy and long-term hepatic function in advanced/decompensated cirrhosis: Real-world experience from HCV-TARGET cohort. J Hepatol 2020; 73:540.</a></li><li><a class="nounderline abstract_t">Chhatwal J, Samur S, Bethea ED, et al. Transplanting hepatitis C virus-positive livers into hepatitis C virus-negative patients with preemptive antiviral treatment: A modeling study. Hepatology 2018; 67:2085.</a></li><li><a class="nounderline abstract_t">Prenner SB, VanWagner LB, Flamm SL, et al. Hepatocellular carcinoma decreases the chance of successful hepatitis C virus therapy with direct-acting antivirals. J Hepatol 2017; 66:1173.</a></li><li><a class="nounderline abstract_t">Beste LA, Green PK, Berry K, et al. Effectiveness of hepatitis C antiviral treatment in a USA cohort of veteran patients with hepatocellular carcinoma. J Hepatol 2017; 67:32.</a></li><li><a class="nounderline abstract_t">Verna EC. The dynamic landscape of liver transplant in the era of effective hepatitis C virus therapy. Hepatology 2017; 65:763.</a></li><li><a class="nounderline abstract_t">Terrault NA, McCaughan GW, Curry MP, et al. International Liver Transplantation Society Consensus Statement on Hepatitis C Management in Liver Transplant Candidates. Transplantation 2017; 101:945.</a></li><li><a class="nounderline abstract_t">Curry MP, Forns X, Chung RT, et al. Sofosbuvir and ribavirin prevent recurrence of HCV infection after liver transplantation: an open-label study. Gastroenterology 2015; 148:100.</a></li><li><a class="nounderline abstract_t">Manns M, Samuel D, Gane EJ, et al. Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial. Lancet Infect Dis 2016; 16:685.</a></li><li><a class="nounderline abstract_t">Bourlière M, Bronowicki JP, de Ledinghen V, et al. Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: a randomised, double-blind, phase 2 trial (SIRIUS). Lancet Infect Dis 2015; 15:397.</a></li><li><a class="nounderline abstract_t">Poordad F, Schiff ER, Vierling JM, et al. Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post-liver transplantation recurrence. Hepatology 2016; 63:1493.</a></li><li><a class="nounderline abstract_t">Bowring MG, Kucirka LM, Massie AB, et al. Changes in Utilization and Discard of Hepatitis C-Infected Donor Livers in the Recent Era. Am J Transplant 2017; 17:519.</a></li><li><a class="nounderline abstract_t">Levitsky J, Formica RN, Bloom RD, et al. The American Society of Transplantation Consensus Conference on the Use of Hepatitis C Viremic Donors in Solid Organ Transplantation. Am J Transplant 2017; 17:2790.</a></li><li><a class="nounderline abstract_t">Vargas HE, Laskus T, Wang LF, et al. Outcome of liver transplantation in hepatitis C virus-infected patients who received hepatitis C virus-infected grafts. Gastroenterology 1999; 117:149.</a></li><li><a class="nounderline abstract_t">Velidedeoglu E, Desai NM, Campos L, et al. The outcome of liver grafts procured from hepatitis C-positive donors. Transplantation 2002; 73:582.</a></li><li><a class="nounderline abstract_t">Lai JC, O'Leary JG, Trotter JF, et al. Risk of advanced fibrosis with grafts from hepatitis C antibody-positive donors: a multicenter cohort study. Liver Transpl 2012; 18:532.</a></li><li><a class="nounderline abstract_t">Northup PG, Argo CK, Nguyen DT, et al. Liver allografts from hepatitis C positive donors can offer good outcomes in hepatitis C positive recipients: a US National Transplant Registry analysis. Transpl Int 2010; 23:1038.</a></li><li><a class="nounderline abstract_t">Cotter TG, Paul S, Sandıkçı B, et al. Increasing Utilization and Excellent Initial Outcomes Following Liver Transplant of Hepatitis C Virus (HCV)-Viremic Donors Into HCV-Negative Recipients: Outcomes Following Liver Transplant of HCV-Viremic Donors. Hepatology 2019; 69:2381.</a></li><li><a class="nounderline abstract_t">Burton JR Jr, Terrault NA, Goldberg DS, et al. Liver and Kidney Recipient Selection of Hepatitis C Virus Viremic Donors: Meeting Consensus Report From the 2019 Controversies in Transplantation. Transplantation 2020; 104:476.</a></li><li class="breakAll">The American Association for the Study of Liver Diseases and the Infectious Diseases Society of America. HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C. https://www.hcvguidelines.org/ (Accessed on October 28, 2020).</li><li><a class="nounderline abstract_t">Cotter TG, Aronsohn A, Reddy KG, Charlton M. Liver Transplantation of HCV-viremic Donors Into HCV-negative Recipients in the United States: Increasing Frequency With Profound Geographic Variation. Transplantation 2021; 105:1285.</a></li><li><a class="nounderline abstract_t">Kwong AJ, Wall A, Melcher M, et al. Liver transplantation for hepatitis C virus (HCV) non-viremic recipients with HCV viremic donors. Am J Transplant 2019; 19:1380.</a></li><li><a class="nounderline abstract_t">Bethea E, Arvind A, Gustafson J, et al. Immediate administration of antiviral therapy after transplantation of hepatitis C-infected livers into uninfected recipients: Implications for therapeutic planning. Am J Transplant 2020; 20:1619.</a></li><li><a class="nounderline abstract_t">Terrault NA, Burton J, Ghobrial M, et al. Prospective Multicenter Study of Early Antiviral Therapy in Liver and Kidney Transplant Recipients of HCV-Viremic Donors. Hepatology 2021; 73:2110.</a></li><li><a class="nounderline abstract_t">Verna EC, Tsapepas D, Emond JC, et al. Utilization of Hepatitis C Virus (HCV)-Viremic Organs for HCV Negative Recipients: Is Practice Speeding Past the Evidence? Hepatology 2020; 71:4.</a></li><li><a class="nounderline abstract_t">Polanco NP, Goldberg D. Transplanting Livers From "HCV-Positive" Donors To HCV-Negative Recipients: Increased Experience But Many Unanswered Questions. Am J Gastroenterol 2020; 115:1022.</a></li><li><a class="nounderline abstract_t">Verna EC, Goldberg DS. Hepatitis C viremic donors for hepatitis C nonviremic liver transplant recipients: Ready for prime time? Liver Transpl 2018; 24:12.</a></li><li class="breakAll">American Association for the Study of Liver Diseases (AASLD). HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C. https://www.hcvguidelines.org/ (Accessed on November 25, 2017).</li><li><a class="nounderline abstract_t">Adebajo CO, Talwalkar JA, Poterucha JJ, et al. Ultrasound-based transient elastography for the detection of hepatic fibrosis in patients with recurrent hepatitis C virus after liver transplantation: a systematic review and meta-analysis. Liver Transpl 2012; 18:323.</a></li><li><a class="nounderline abstract_t">Carrión JA, Fernández-Varo G, Bruguera M, et al. Serum fibrosis markers identify patients with mild and progressive hepatitis C recurrence after liver transplantation. Gastroenterology 2010; 138:147.</a></li><li><a class="nounderline abstract_t">Cholongitas E, Tsochatzis E, Goulis J, Burroughs AK. Noninvasive tests for evaluation of fibrosis in HCV recurrence after liver transplantation: a systematic review. Transpl Int 2010; 23:861.</a></li><li><a class="nounderline abstract_t">Picciotto FP, Tritto G, Lanza AG, et al. Sustained virological response to antiviral therapy reduces mortality in HCV reinfection after liver transplantation. J Hepatol 2007; 46:459.</a></li><li><a class="nounderline abstract_t">Dhanasekaran R, Sanchez W, Mounajjed T, et al. Impact of fibrosis progression on clinical outcome in patients treated for post-transplant hepatitis C recurrence. Liver Int 2015; 35:2433.</a></li><li><a class="nounderline abstract_t">Cholankeril G, Li AA, March KL, et al. Improved Outcomes in HCV Patients Following Liver Transplantation During the Era of Direct-Acting Antiviral Agents. Clin Gastroenterol Hepatol 2018; 16:452.</a></li><li><a class="nounderline abstract_t">Crespo G, Trota N, Londoño MC, et al. The efficacy of direct anti-HCV drugs improves early post-liver transplant survival and induces significant changes in waiting list composition. J Hepatol 2018; 69:11.</a></li><li><a class="nounderline abstract_t">Gurusamy KS, Tsochatzis E, Toon CD, et al. Antiviral prophylaxis for the prevention of chronic hepatitis C virus in patients undergoing liver transplantation. Cochrane Database Syst Rev 2013; :CD006573.</a></li><li><a class="nounderline abstract_t">Bzowej N, Nelson DR, Terrault NA, et al. PHOENIX: A randomized controlled trial of peginterferon alfa-2a plus ribavirin as a prophylactic treatment after liver transplantation for hepatitis C virus. Liver Transpl 2011; 17:528.</a></li><li><a class="nounderline abstract_t">Reau N, Kwo PY, Rhee S, et al. Glecaprevir/Pibrentasvir Treatment in Liver or Kidney Transplant Patients With Hepatitis C Virus Infection. Hepatology 2018; 68:1298.</a></li><li><a class="nounderline abstract_t">Agarwal K, Castells L, Müllhaupt B, et al. Sofosbuvir/velpatasvir for 12 weeks in genotype 1-4 HCV-infected liver transplant recipients. J Hepatol 2018; 69:603.</a></li><li><a class="nounderline abstract_t">Kwok RM, Ahn J, Schiano TD, et al. Sofosbuvir plus ledispasvir for recurrent hepatitis C in liver transplant recipients. Liver Transpl 2016; 22:1536.</a></li><li><a class="nounderline abstract_t">Saxena V, Khungar V, Verna EC, et al. Safety and efficacy of current direct-acting antiviral regimens in kidney and liver transplant recipients with hepatitis C: Results from the HCV-TARGET study. Hepatology 2017; 66:1090.</a></li><li><a class="nounderline abstract_t">Abaalkhail F, Elsiesy H, Elbeshbeshy H, et al. Treatment of Patients With Hepatitis C Virus Infection With Ledipasvir-Sofosbuvir in the Liver Transplant Setting. Transplantation 2017; 101:2739.</a></li><li><a class="nounderline abstract_t">Houssel-Debry P, Coilly A, Fougerou-Leurent C, et al. 12 Weeks of a Ribavirin-Free Sofosbuvir and Nonstructural Protein 5A Inhibitor Regimen Is Enough to Treat Recurrence of Hepatitis C After Liver Transplantation. Hepatology 2018; 68:1277.</a></li><li><a class="nounderline abstract_t">Levitsky J, Verna EC, O'Leary JG, et al. Perioperative Ledipasvir-Sofosbuvir for HCV in Liver-Transplant Recipients. N Engl J Med 2016; 375:2106.</a></li><li><a class="nounderline abstract_t">Neff GW, O'Brien CB, Nery J, et al. Factors that identify survival after liver retransplantation for allograft failure caused by recurrent hepatitis C infection. Liver Transpl 2004; 10:1497.</a></li><li><a class="nounderline abstract_t">Biggins SW, Beldecos A, Rabkin JM, Rosen HR. Retransplantation for hepatic allograft failure: prognostic modeling and ethical considerations. Liver Transpl 2002; 8:313.</a></li><li><a class="nounderline abstract_t">Sheiner PA, Schluger LK, Emre S, et al. Retransplantation for recurrent hepatitis C. Liver Transpl Surg 1997; 3:130.</a></li><li><a class="nounderline abstract_t">Rosen HR, O'Reilly PM, Shackleton CR, et al. Graft loss following liver transplantation in patients with chronic hepatitis C. Transplantation 1996; 62:1773.</a></li><li><a class="nounderline abstract_t">Berenguer M, Prieto M, Palau A, et al. Severe recurrent hepatitis C after liver retransplantation for hepatitis C virus-related graft cirrhosis. Liver Transpl 2003; 9:228.</a></li><li><a class="nounderline abstract_t">Roayaie S, Schiano TD, Thung SN, et al. Results of retransplantation for recurrent hepatitis C. Hepatology 2003; 38:1428.</a></li><li><a class="nounderline abstract_t">Rosen HR, Prieto M, Casanovas-Taltavull T, et al. Validation and refinement of survival models for liver retransplantation. Hepatology 2003; 38:460.</a></li><li><a class="nounderline abstract_t">Alamo JM, Gómez MA, Pareja F, et al. Morbidity and mortality in liver retransplantation. Transplant Proc 2006; 38:2475.</a></li><li><a class="nounderline abstract_t">Ercolani G, Grazi GL, Ravaioli M, et al. Histological recurrent hepatitis C after liver transplantation: Outcome and role of retransplantation. Liver Transpl 2006; 12:1104.</a></li><li><a class="nounderline abstract_t">McCashland T, Watt K, Lyden E, et al. Retransplantation for hepatitis C: results of a U.S. multicenter retransplant study. Liver Transpl 2007; 13:1246.</a></li></ol></div><div id="topicVersionRevision">Topic 4583 Version 48.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="http://www.unos.org/" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : http://www.unos.org/ (Accessed on March 27, 2007).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17164125" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Hepatitis C virus and liver transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29199144" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Alcoholic Liver Disease Replaces Hepatitis C Virus Infection as the Leading Indication for Liver Transplantation in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1377143" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Recurrent and acquired hepatitis C viral infection in liver transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8607170" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Clinical and histologic patterns of early graft failure due to recurrent hepatitis C in four patients after liver transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11870384" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Hepatitis C virus kinetics during and immediately after liver transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8536853" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : A longitudinal analysis of hepatitis C virus replication following liver transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1313453" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Reinfection of liver graft by hepatitis C virus after liver transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12362293" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Natural history of recurrent hepatitis C.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8596547" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Long-term outcome of hepatitis C infection after liver transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9024312" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Hepatitis C after orthotopic liver transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10464137" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : European collaborative study on factors influencing outcome after liver transplantation for hepatitis C. European Concerted Action on Viral Hepatitis (EUROHEP) Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10573532" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Evolution of hepatitis C virus quasispecies in patients with severe cholestatic hepatitis after liver transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10500076" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Association of multispecific CD4(+) response to hepatitis C and severity of recurrence after liver transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11830194" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Effect of race on outcome of orthotopic liver transplantation: a cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17600360" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : A prospective evaluation of fibrosis progression in patients with recurrent hepatitis C virus following liver transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17370330" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Liver transplantation for HCV cirrhosis: improved survival in recent years and increased severity of recurrent disease in female recipients: results of a long term retrospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15349910" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Hepatitis C recurrence is more severe after living donor compared to cadaveric liver transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15376308" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Histologic recurrence of chronic hepatitis C virus in patients after living donor and deceased donor liver transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12829984" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : A model to predict severe HCV-related disease following liver transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7927244" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : The course of hepatitis C virus infection after liver transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9791154" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Clinical outcome of patients infected with hepatitis C virus infection on survival after primary liver transplantation under tacrolimus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15519657" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Fibrosis progression after liver transplantation in patients with recurrent hepatitis C.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16496308" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Hepatic venous pressure gradient identifies patients at risk of severe hepatitis C recurrence after liver transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16184568" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Early hepatic stellate cell activation predicts severe hepatitis C recurrence after liver transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15763325" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : What determines the natural history of recurrent hepatitis C after liver transplantation?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7698576" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Influence of the genotypes of hepatitis C virus on the severity of recurrent liver disease after liver transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9696025" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Clinical outcome of hepatitis C as a function of mode of transmission.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9175804" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Relationship between hepatitis C genotype and severity of recurrent hepatitis C after liver transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8903372" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Severity of liver disease in liver transplantation recipients with hepatitis C virus infection: relationship to genotype and level of viremia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9731579" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Predictors of patient and graft survival following liver transplantation for hepatitis C.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9457963" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : The influence of hepatitis C virus genotypes on the outcome of liver transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11050065" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Early identification of recipients with progressive histologic recurrence of hepatitis C after liver transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16998365" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Effect of nonviral factors on hepatitis C recurrence after liver transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22172848" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Donor age does not influence 12-month outcome after orthotopic liver transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15140662" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Use of elderly donors (&gt;60 years) for liver transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15707410" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Differential effects of donor age in liver transplant recipients infected with hepatitis B, hepatitis C and without viral hepatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12085366" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Contribution of donor age to the recent decrease in patient survival among HCV-infected liver transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11965581" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Impact of cytomegalovirus infection, year of transplantation, and donor age on outcomes after liver transplantation for hepatitis C.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20420649" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Liver transplantation in the United States, 1999-2008.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8985291" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Long-term outcome of hepatitis C virus infection after liver transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15350002" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Long-term results and modeling to predict outcomes in recipients with HCV infection: results of the NIDDK liver transplantation database.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11910340" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : The association between hepatitis C infection and survival after orthotopic liver transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25985734" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27018088" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Treat chronic hepatitis C virus infection in decompensated cirrhosis - pre- or post-liver transplantation? the ironic conundrum in the era of effective and well-tolerated therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26569658" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Sofosbuvir and Velpatasvir for HCV in Patients with Decompensated Cirrhosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27212241" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Delisting of liver transplant candidates with chronic hepatitis C after viral eradication: A European study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27344058" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Impact of viral eradication with sofosbuvir-based therapy on the outcome of post-transplant hepatitis C with severe fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29535028" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Baseline Factors Associated With Improvements in Decompensated Cirrhosis After Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28842296" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Clinical outcomes of patients undergoing antiviral therapy while awaiting liver transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32243960" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : DAA therapy and long-term hepatic function in advanced/decompensated cirrhosis: Real-world experience from HCV-TARGET cohort.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29222916" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Transplanting hepatitis C virus-positive livers into hepatitis C virus-negative patients with preemptive antiviral treatment: A modeling study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28161470" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Hepatocellular carcinoma decreases the chance of successful hepatitis C virus therapy with direct-acting antivirals.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28267622" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Effectiveness of hepatitis C antiviral treatment in a USA cohort of veteran patients with hepatocellular carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28093781" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : The dynamic landscape of liver transplant in the era of effective hepatitis C virus therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28437387" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : International Liver Transplantation Society Consensus Statement on Hepatitis C Management in Liver Transplant Candidates.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25261839" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Sofosbuvir and ribavirin prevent recurrence of HCV infection after liver transplantation: an open-label study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26907736" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25773757" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: a randomised, double-blind, phase 2 trial (SIRIUS).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26754432" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post-liver transplantation recurrence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27456927" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Changes in Utilization and Discard of Hepatitis C-Infected Donor Livers in the Recent Era.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28556422" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : The American Society of Transplantation Consensus Conference on the Use of Hepatitis C Viremic Donors in Solid Organ Transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10381921" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Outcome of liver transplantation in hepatitis C virus-infected patients who received hepatitis C virus-infected grafts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11889435" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : The outcome of liver grafts procured from hepatitis C-positive donors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22271671" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Risk of advanced fibrosis with grafts from hepatitis C antibody-positive donors: a multicenter cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20444239" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Liver allografts from hepatitis C positive donors can offer good outcomes in hepatitis C positive recipients: a US National Transplant Registry analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30706517" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Increasing Utilization and Excellent Initial Outcomes Following Liver Transplant of Hepatitis C Virus (HCV)-Viremic Donors Into HCV-Negative Recipients: Outcomes Following Liver Transplant of HCV-Viremic Donors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31634329" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Liver and Kidney Recipient Selection of Hepatitis C Virus Viremic Donors: Meeting Consensus Report From the 2019 Controversies in Transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31634329" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Liver and Kidney Recipient Selection of Hepatitis C Virus Viremic Donors: Meeting Consensus Report From the 2019 Controversies in Transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32639400" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Liver Transplantation of HCV-viremic Donors Into HCV-negative Recipients in the United States: Increasing Frequency With Profound Geographic Variation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30378723" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Liver transplantation for hepatitis C virus (HCV) non-viremic recipients with HCV viremic donors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31887236" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Immediate administration of antiviral therapy after transplantation of hepatitis C-infected livers into uninfected recipients: Implications for therapeutic planning.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32926749" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Prospective Multicenter Study of Early Antiviral Therapy in Liver and Kidney Transplant Recipients of HCV-Viremic Donors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31505047" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Utilization of Hepatitis C Virus (HCV)-Viremic Organs for HCV Negative Recipients: Is Practice Speeding Past the Evidence?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32618651" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Transplanting Livers From "HCV-Positive" Donors To HCV-Negative Recipients: Increased Experience But Many Unanswered Questions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29160931" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Hepatitis C viremic donors for hepatitis C nonviremic liver transplant recipients: Ready for prime time?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29160931" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Hepatitis C viremic donors for hepatitis C nonviremic liver transplant recipients: Ready for prime time?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22140010" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Ultrasound-based transient elastography for the detection of hepatic fibrosis in patients with recurrent hepatitis C virus after liver transplantation: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19786026" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Serum fibrosis markers identify patients with mild and progressive hepatitis C recurrence after liver transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20704691" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Noninvasive tests for evaluation of fibrosis in HCV recurrence after liver transplantation: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17196700" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Sustained virological response to antiviral therapy reduces mortality in HCV reinfection after liver transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26058570" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Impact of fibrosis progression on clinical outcome in patients treated for post-transplant hepatitis C recurrence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28838786" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Improved Outcomes in HCV Patients Following Liver Transplantation During the Era of Direct-Acting Antiviral Agents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29481821" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : The efficacy of direct anti-HCV drugs improves early post-liver transplant survival and induces significant changes in waiting list composition.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24297303" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Antiviral prophylaxis for the prevention of chronic hepatitis C virus in patients undergoing liver transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21506241" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : PHOENIX: A randomized controlled trial of peginterferon alfa-2a plus ribavirin as a prophylactic treatment after liver transplantation for hepatitis C virus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29672891" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Glecaprevir/Pibrentasvir Treatment in Liver or Kidney Transplant Patients With Hepatitis C Virus Infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29886154" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Sofosbuvir/velpatasvir for 12 weeks in genotype 1-4 HCV-infected liver transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27543748" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Sofosbuvir plus ledispasvir for recurrent hepatitis C in liver transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28504842" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Safety and efficacy of current direct-acting antiviral regimens in kidney and liver transplant recipients with hepatitis C: Results from the HCV-TARGET study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28795982" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Treatment of Patients With Hepatitis C Virus Infection With Ledipasvir-Sofosbuvir in the Liver Transplant Setting.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29633389" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : 12 Weeks of a Ribavirin-Free Sofosbuvir and Nonstructural Protein 5A Inhibitor Regimen Is Enough to Treat Recurrence of Hepatitis C After Liver Transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27959735" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Perioperative Ledipasvir-Sofosbuvir for HCV in Liver-Transplant Recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15558835" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Factors that identify survival after liver retransplantation for allograft failure caused by recurrent hepatitis C infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11965573" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Retransplantation for hepatic allograft failure: prognostic modeling and ethical considerations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9346726" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Retransplantation for recurrent hepatitis C.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8990361" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Graft loss following liver transplantation in patients with chronic hepatitis C.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12619018" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Severe recurrent hepatitis C after liver retransplantation for hepatitis C virus-related graft cirrhosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14647054" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Results of retransplantation for recurrent hepatitis C.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12883491" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Validation and refinement of survival models for liver retransplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17097972" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Morbidity and mortality in liver retransplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16710855" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Histological recurrent hepatitis C after liver transplantation: Outcome and role of retransplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17763405" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Retransplantation for hepatitis C: results of a U.S. multicenter retransplant study.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
